Key Takeaways
- A study from the University of Macau analyzes the global patent landscape of optogenetics, noting technological advancements and challenges.
- Optogenetics, initially focused on neuroscience, is now expanding into synthetic biology and clinical medicine, with treatments for retinal diseases leading clinical trials.
- Despite promising developments, no optogenetics products have received market approval due to technical and regulatory hurdles.
Research Insights on Optogenetics
A research team led by Hu Yuanjia from the University of Macau (UM) published findings in *Nature Biotechnology*, exploring the global patent landscape of optogenetics. The study, conducted by scientists at UM’s Institute of Chinese Medical Sciences and the State Key Laboratory of Mechanism and Quality of Chinese Medicine, in collaboration with Zhang Yanfei from the Tianjin Institute of Industrial Biotechnology, analyzes technological advancements, industrial challenges, and future clinical prospects in this emerging field.
Optogenetics employs photosensitive proteins to regulate cellular activities with high precision, allowing control over biological processes at the millisecond and single-cell levels. Originally focused on neuroscience, the technology has expanded to synthetic biology, natural product biosynthesis, and clinical medicine.
The team studied 332 patent families, discovering that global patent applications in optogenetics peaked in 2019 but declined significantly afterward. Notably, blue light-activated optogenetic tools accounted for 41 percent of innovations and have seen widespread applications in clinical medicine and cell biology. The treatment of retinal diseases has emerged as the most advanced area of clinical translation, with 11 clinical trials registered by the end of 2023.
However, the study emphasizes that no optogenetics products have received market approval yet, underscoring ongoing industrial and clinical application challenges. Major technical limitations identified include restricted tissue penetration, insufficient performance of photosensitive proteins, and inadequate safety data for human applications. Additionally, the absence of adaptive regulatory frameworks and rising ethical concerns complicate development.
Looking ahead, the researchers suggest that future breakthroughs may hinge on multidisciplinary integration, merging optogenetics with technologies like calcium channel regulation, upconversion luminescence materials, and organoid systems to create more clinically viable therapeutic models. The study indicates a resurgence in the sector, with patent publications related to optogenetics increasing again in 2024 and 2025 after a decline in 2023. New patents focusing on light-controlled immune cell infiltration and near-infrared light-regulated immune pathways signify emerging areas of interest.
The number of related clinical trials has risen to 16, including MCO-010 developed by Nanoscope Therapeutics, which has completed a Phase IIb trial and is initiating a rolling Biologics License Application with the US Food and Drug Administration. Multiple funding bodies, including the Science and Technology Development Fund (FDCT) and UM, supported the research.
The content above is a summary. For more details, see the source article.